[NP-Clinical] Re: Handheld Inhalers

[Linda Follenweider]

Here is a nice summation.  Understand that CFC propellant contributes to
less than 1% of ozone depletion.  Costs for medication for SABA has
skyrocketed since many companies have stopped producing the CFC propellant
MDIs .which also resulted in a national shortage earlier this year.

Approximately 95 percent of the short-acting beta-agonist inhalers sold in
2005 contained chlorofluorocarbon (CFC) propellants, according to IMS Health
information. Under provisions in the Montreal Protocol on Substances that
Deplete the Ozone Layer, an international agreement that requires the
phase-out of substances that deplete the ozone layer, MDIs containing CFC
propellants qualify for removal from the marketplace. In March 2005, the FDA
issued its final rule for the removal of the essential use exemption for
albuterol, which currently permits the use of CFC-containing albuterol
inhalers despite environmental concerns. Under the rule, all production and
sales of albuterol CFC MDIs in the U.S. are required to cease by the end of
2008. The XOPENEX MDI uses an HFA propellant and does not contain CFCs.
Linda Folllenweider


On 12/31/06, mfnp at cox.net <mfnp at cox.net> wrote:
>
> Does anyone know if there is a specific "decree" , date of if it exists,
> that handheld inhalers using the normal ingredients most of the simple
> inhalants, i.e., Albuterol, use as their propellants that is taking these
> off the market? Our supplier is telling us this, and I can not find anything
> on the FDA, CDC, Medscape etc. sites? Thanks, Marty
>
>
> _______________________________________________
> NP-Clinical mailing list
> NP-Clinical at nurse.net
> http://lists.nurse.net/mailman/listinfo/np-clinical
>
> FnP Associates offers a complimentary continuing education program.
> Pain: Current Understanding of Assessment, Management, and Treatments
> Receive 6.0 Contact Hours of Pharmacology
> NPCENTRAL.NET/CE/PAIN <http://npcentral.net/CE/PAIN>
>
>


-- 
Linda M. Follenweider MS, APN, BC
Family Nurse Practitioner
Clinical Director Asthma Center at Fantus



The contents of this e-mail message and any attachments are private and
confidential communications intended solely for the addressee(s) named
in this message. If you are not the intended recipient of this message,
please 1) immediately notify the sender by reply e-mail and then delete
this message and its attachments and 2) do not read, use, distribute
disclose or copy this message and/or any attachments.

-- 
Linda M. Follenweider MS, APN, BC
Family Nurse Practitioner
Clinical Director Asthma Center at Fantus
Cook County Bureau of Health Services
Fantus-Second Floor
1901 W. Harrison
Chicago, IL 60612

office: 312-864-7697
pager: 312-333-4298
fax: 312-864-7584
e-mail: follenweider at gmail.com


The contents of this e-mail message and any attachments are private and
confidential communications intended solely for the addressee(s) named
in this message. If you are not the intended recipient of this message,
please 1) immediately notify the sender by reply e-mail and then delete
this message and its attachments and 2) do not read, use, distribute
disclose or copy this message and/or any attachments.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://lists.nurse.net/pipermail/np-clinical/attachments/20070101/50e27e2b/attachment.html